Company Filing History:
Years Active: 2015-2016
Title: The Innovations of Dong-Sup Lee
Introduction
Dong-Sup Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 3 patents to his name, his work has the potential to impact cancer treatment and research significantly.
Latest Patents
One of Dong-Sup Lee's latest patents is focused on a human monoclonal antibody that neutralizes vascular endothelial growth factor receptor. This invention relates specifically to human ScFv molecules that inhibit angiogenesis and can be used in cancer treatment. The disclosed monoclonal antibody demonstrates excellent neutralizing ability in living cells, outperforming commercially available antibodies against vascular endothelial growth factor receptor. It has shown effectiveness not only in humans but also in mice and rats, making it a valuable asset in anticancer studies.
Career Highlights
Dong-Sup Lee is currently associated with Pharmabcine Inc., where he continues to innovate in the field of biotechnology. His work is characterized by a commitment to advancing medical science and improving treatment options for cancer patients.
Collaborations
He has collaborated with notable colleagues, including Jin-San Yoo and Weon-Sup Lee, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Dong-Sup Lee's contributions to the field of biotechnology, particularly through his patents on monoclonal antibodies, highlight his role as a key inventor in cancer research. His work promises to enhance treatment options and improve patient outcomes in the future.